What clinical trials have tested medical-grade honey eye drops and what were their findings?
Executive summary
Medical‑grade honey eye preparations have been tested in a limited but growing set of randomized and controlled clinical trials for conditions including vernal keratoconjunctivitis (VKC), dry eye disease and meibomian gland dysfunction (MGD), blepharitis and even adenoviral conjunctivitis; results are encouraging in several small trials but heterogeneous methods, small sample sizes and adjunctive use with standard therapy constrain firm conclusions [1] [2] [3] [4] [5]. Systematic reviews note promise for manuka and other Leptospermum‑derived formulations but call for larger, higher‑quality randomized trials to confirm efficacy and safety [5] [6].
1. The VKC double‑blind trial that surprised reviewers
A 2014 double‑blind randomized trial of a honey eye drop in patients with vernal keratoconjunctivitis (60 completers) reported reduced conjunctival redness and limbal papillae in the honey group compared with placebo, while also recording a statistically significant increase in intraocular pressure in the honey arm—an outcome the authors flagged as unexpected and clinically relevant [1] [7]. That single‑trial evidence is cited repeatedly in reviews as an early clinical signal but reviewers and guideline‑minded authors treat it cautiously because of sample size, population specifics and safety signals that require replication [1] [6].
2. Trials targeting dry eye and MGD: formulations, concentrations and mixed results
Multiple trials have tested formulated medical‑grade honey or Leptospermum spp (manuka) preparations for evaporative dry eye and MGD with mixed endpoints: some studies reported improvements in subjective symptom scores and tear‑film stability while others found no change in corneal staining or objective markers over short treatment windows (4–8 weeks) [3] [8]. A 2020 British Journal of Ophthalmology randomized study comparing a Leptospermum spp eye drop to conventional lubricant found no significant change in corneal staining after 4 weeks, although other longer or differently powered studies have reported staining improvements at 8 weeks—illustrating inconsistencies in outcomes tied to study design and duration [3].
3. Low‑dose honey clinical trial addressing safety and cell biology
A recent translational clinical study combined in‑vitro work with a randomized clinical arm of 80 dry eye patients treated with a 1% w/v honey ophthalmic formulation versus placebo for three months; investigators emphasized dilution to manage honey’s osmolarity, pH and sterilization challenges and reported improvements in subjective symptoms, tear break‑up time and Schirmer’s testing in the treated group in the published report [2] [9]. The study explicitly framed its low concentration as an effort to avoid irritation reported with higher concentrations (16–70%) in earlier work, but it remains one trial and needs independent replication [2].
4. Other conditions and regional trials: blepharitis and viral conjunctivitis
Separate randomized work has explored manuka honey microemulsion for blepharitis and small trials have tested honey alongside standard care for adenoviral keratoconjunctivitis; a Gaza conference‑reported trial found symptom relief when 16.5% Manuka drops were added to steroid treatment, while industry‑linked microemulsion and microemulsion‑cream studies report tolerability and some benefit for lid disease—again often as adjuncts rather than standalone therapies [4] [3] [10].
5. What systematic reviews and clinical commentaries conclude
Systematic reviews synthesize these disparate trials as “promising but not definitive,” highlighting consistent signals for symptomatic improvement and some objective tear‑film benefits with manuka and medical honey, but they emphasize heterogeneity in honey type, concentration, formulation, outcome measures and trial quality, concluding that larger, better‑powered randomized controlled trials are required [5] [6] [10]. Professional commentaries note ongoing academic trials (e.g., QUT plans) and caution that commercially marketed claims may outpace the evidence [11].
6. Limitations, safety signals and potential biases to weigh
Across the literature there are three recurring caveats: variable honey chemistry (manuka vs other species) and MGO content, formulation issues (viscosity, osmolarity, pH and sterilization) that affect tolerability, and frequent use of honey drops as add‑ons to conventional therapy which complicates attribution of benefit; furthermore small sample sizes and short follow‑ups limit detection of rare harms such as the intraocular pressure change noted in the VKC trial [2] [1] [3] [6]. Industry and marketing channels sometimes amplify positive patient‑facing results [12] [8], so clinical decisions should rely on peer‑reviewed trials and guidance rather than promotional materials.
Conclusion: cautious optimism, not endorsement
Clinical trials to date show medical‑grade honey eye drops can produce symptomatic and, in some studies, objective improvements for dry eye, MGD and certain inflammatory conjunctivitides, but evidence is heterogeneous, often adjunctive and underpowered; definitive practice‑changing proof awaits larger, standardized randomized trials that address formulation, dosing, long‑term safety and independent replication [5] [6] [2].